Prelude Capital Management LLC lowered its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 6.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,365 shares of the company’s stock after selling 1,200 shares during the period. Prelude Capital Management […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak R. Azamian sold 8,000 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $17.23, for a total transaction of $137,840.00. Following the sale, the chief executive officer now owns 902,106 shares in the […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak R. Azamian sold 8,000 shares of the stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $17.23, for a total transaction of $137,840.00. Following the completion of the transaction, the chief executive officer now owns 902,106 shares […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) Director Elizabeth Yeu Lin bought 9,506 shares of the stock in a transaction on Tuesday, August 15th. The shares were bought at an average price of $16.80 per share, for a total transaction of $159,700.80. Following the completion of the transaction, the director now directly owns 15,866 […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) Director Elizabeth Yeu Lin bought 9,506 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were acquired at an average cost of $16.80 per share, for a total transaction of $159,700.80. Following the purchase, the director now directly owns 15,866 […]